Alnylam has pushed back the data readout for its HELIOS-B trial from early 2024 to June/July 2024, causing a 10% decline in the stock price. The company has made changes to the study duration, primary ...
Please provide your email address to receive an email when new articles are posted on . Alnylam announced positive top-line results of its phase 3 trial of vutrisiran for the treatment of ATTR ...
− Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and Quality of Life, Compared to Placebo – “The HELIOS-B study continues to deliver a robust data ...
− Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively – − Reduced All-Cause Mortality by 36% ...
LONDON -- Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III ...
The small interfering RNA (siRNA) agent vutrisiran has beneficial effects on cardiac biomarkers that are seen as early as 6 months in patients with transthyretin amyloidosis with cardiomyopathy ...
Alnylam Pharmaceuticals Inc.’s decision to change its analysis plan for the phase III Helios-B trial of RNAi therapeutic Amvuttra (vutrisiran) to treat transthyretin amyloidosis with cardiomyopathy, ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback